Is bladder biopsy necessary at three or six months post BCG therapy?

Malkowicz, 2000, Intravesical therapy for superficial bladder cancer, Semin Urol Oncol, 1, 280 Lamm, 1992, Carcinoma in Situ, Urol Clin North Am, 19, 499 Lamm, 1990, Maintenance BCG immunotherapy of superficial bladder cancer, J Urol., 143, 341 Lamm, 1992, 17 Lamm, 2000, Maintenance Bacillus Calmette-Guerin Immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5 Fleming, 1997 Dalbagni, 1999, Transurethral biopsy of the bladder necessary after three months to evaluate response to Bacillus Clamette-Guerin therapy?, J Urol, 162, 708, 10.1097/00005392-199909010-00020 Grossfeld, 2001, Evaluation of asymptomatic microscopic hematuria in adults, Urol, 57, 604, 10.1016/S0090-4295(01)00920-7 Oosterlinck, 2001, The management of superficial bladder cancer, BJU Int, 87, 135, 10.1046/j.1464-410x.2001.00948.x Herr, 1989, Superficial bladder cancer treated with Bacillus Calmette-Guerin, J Urol, 141, 22, 10.1016/S0022-5347(17)40575-1 Cookson, 1997, The treated natural history of high risk superficial bladder cancer, J Urol, 158, 62, 10.1097/00005392-199707000-00017 Holmang, 1995, The relationship among multiple recurrences, progression, and prognosis of patients with stages TA and T1 transitional cell cancer of the bladder followed for at least 20 years, J Urol, 153, 1823, 10.1016/S0022-5347(01)67321-X Stapp, 2000, Intravesical Therapy and Follow-up of Superficial Transitional Cell Carcinoma of the Bladder, Brazilian J Urol, 26, 242